UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000032153 |
|---|---|
| Receipt number | R000036679 |
| Scientific Title | A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer |
| Date of disclosure of the study information | 2018/04/09 |
| Last modified on | 2018/04/08 15:10:05 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer
Acronym
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by FEC in operable breast cancer
Scientific Title
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer
Scientific Title:Acronym
A phase II neoadjuvant trial of sequential nab-paclitaxel followed by FEC in operable breast cancer
Region
| Japan |
Condition
Condition
breast cancer
Classification by specialty
| Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of neoadjuvant chemotherapy of sequential nab-paclitaxel followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
Clinical response
Key secondary outcomes
Pathological complete response (pCR)
Safety
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
neoadjuvant sequential 4 cycle nab-paclitaxel tri-weekly, with trastuzumab in HER2-positive patients, followed by 4 cycle 5-fluorouracil/epirubicine/cyclophosphamide (FEC) tri-weekly
nab-paclitaxel 4cycle
nab-paclitaxel 260mg/m2, day1, q3w
HER2-positive disease, trastuzumab with nab-paclitaxel, 8 mg/kg loading dose on
cycle 1, day 1 followed by doses of 6 mg/kg on day 1 of subsequent cycles
FEC 4cycle
5-Fluorouracil 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2, day 1, q3w
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Female
Key inclusion criteria
1)Histologically confirmed operable breast c ancer
2)Clinical stage 1, 2, 3
3)Operable breast cancer in neoadjuvant setting
4)Over 20 year-old female
5)Previously untreated by operation, radiotherapy, chemotherapy, endocrine therapy
6)Exhibited adequate organ function
7)Performance status(PS) 0-1
8)Signed written informed consent
Key exclusion criteria
1)Known hypersensitivity to human serum alb umin
2)Concurrent, serious or uncontrolled infect ions
3)Inadequately controlled or serious history of cardiac disease
4)Confirmed symptomatic brain metastasis
5)Current pregnancy and lactation, or possib ility of pregnancy
6)Known drug allergy to any of study drugs
7)Assessment by investigator that subject un able to comply with protocol
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yutaka Mizuno |
Organization
Yokkaichi Municipal Hospital
Division name
Department of breast surgery
Zip code
Address
2-2-37 Shibata Yokkaichi-city Mie
TEL
059-354-1111
mizunoy729@yokkaichihp01.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yutaka Mizuno |
Organization
Yokkaichi Municipal Hospital
Division name
Department of breast surgery
Zip code
Address
2-2-37 Shibata Yokkaichi-city Mie
TEL
059-354-1111
Homepage URL
mizunoy729@yokkaichihp01.jp
Sponsor or person
Institute
Yokkaichi Municipal Hospital
Institute
Department
Personal name
Funding Source
Organization
Yokkaichi Municipal Hospital
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
市立四日市病院（三重県）
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 04 | Month | 09 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2014 | Year | 03 | Month | 06 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 03 | Month | 20 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 04 | Month | 08 | Day |
Last modified on
| 2018 | Year | 04 | Month | 08 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036679
